Brought to you by 
Eddingpharm gets rights to Immutep's ImmuFact IMP321
03 Feb 2023
Executive Summary
Specialty pharmaceuticals company Eddingpharm International Holdings Ltd. licensed exclusive rights to develop, manufacture, and sell oncology firm Immutep SA’s ImmuFact IMP321 in China, Hong Kong, Macau, and Taiwan.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eddingpharm gets rights to Immutep's ImmuFact IMP321
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice